← All trials
NCT07285291
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2026
- Primary completion
- Dec 22, 2026
- Completion date
- Dec 29, 2026
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taisho PharmaceuticalLead sponsor
- Taisho PharmaceuticalOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.